Today, the IRS issued Notice 2011-5, which sets forth revised debit card rules for OTC drugs. The new notice revises the prior rules for OTC drugs from IRS Notice 2010-59 issued earlier this year. Both of these notices implement the change from the Affordable Care Act prohibiting reimbursement from a health FSA or HRA for an OTC drug, unless the participant has a written prescription. The new Notice 2011-5 provides that health FSA and HRA debit cards may continue to be used for OTC drugs if the OTC drug is dispensed by a pharmacist, the OTC drug has a prescription number, other requirements applicable to prescribed drugs are followed, and the applicable provisions of Notice 2010-59 are followed (unless modified by Notice 2011-5). Prior to Notice 2011-5 certain debit card vendors stated that they would have to turn off reimbursement for both prescribed and OTC drugs, because their systems could not differentiate between prescribed and OTC drugs. This Notice now allows reimbursements for prescribed drugs to continue as normal, as well as provides relaxed rules for OTC drugs that are fulfilled by a pharmacist.
http://www.irs.gov/pub/irs-drop/n-11-05.pdfDisclaimer
While we are pleased to have you contact us by telephone, surface mail, electronic mail, or by facsimile transmission, contacting Kilpatrick Townsend & Stockton LLP or any of its attorneys does not create an attorney-client relationship. The formation of an attorney-client relationship requires consideration of multiple factors, including possible conflicts of interest. An attorney-client relationship is formed only when both you and the Firm have agreed to proceed with a defined engagement.
DO NOT CONVEY TO US ANY INFORMATION YOU REGARD AS CONFIDENTIAL UNTIL A FORMAL CLIENT-ATTORNEY RELATIONSHIP HAS BEEN ESTABLISHED.
If you do convey information, you recognize that we may review and disclose the information, and you agree that even if you regard the information as highly confidential and even if it is transmitted in a good faith effort to retain us, such a review does not preclude us from representing another client directly adverse to you, even in a matter where that information could be used against you.
